The Research Animal Support Facility (RASF) has been a shared resource since the original CCSG was awarded in 1975 and exists to support ongoing clinical and basic cancer research involving laboratory animals at MDACC. The RASF has components located in Houston at MDACC (2 campuses), and in Smithville in the Department of Carcinogenesis. All animal facilities are accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International, have Animal Welfare Assurance approval (A3343-01), and are registered as research animal facilities with the United States Department of Agriculture (USDA) (74-R-065). The Research Animal Support Facility Houston (RASFH) is directed by Peggy T. Tinkey, D.V.M. The RASFH encompasses approximately 99,089 sq. ft. of space and provides housing, procedure space, veterinary care, and quality assurance programs for animals used in cancer research. Clinical, surgical, imaging, radiation therapy, and pathology laboratory facilities and services are provided. Existing technical services have been extended to the South Campus facility, and new services added since the last CCSG renewal include computerized animal pedigree and medical history applications, preclinical toxicology services, and increased transportation services. New equipment includes automated multi-species hematology and chemistry analyzers, patient monitoring systems, automated bedding dispensing systems and waste containers, cargo van, and 100 ventilated rodent rack/cage systems. The RASFH has 122 personnel, which includes 11 veterinarians, 2 associate directors, 1 administrator, 2 section managers, 1 project manager, 10 laboratory personnel, 77 animal care personnel, and 17 clerical/support staff. Dr. Tinkey coordinates the daily operations of the RASFH. Five faculty veterinarians direct the 5 service sections that provide facilities, equipment, and services to research animal users. Funding for the RASFH is currently provided by the CCSG (6%), user fees (39%), institutional support (53%) and other funds (2%). In the past 5 years, the RASFH has been used by 319 investigators supporting 20 different CCSG programs. Peer-reviewed investigators represent 92% of the RASFH user utilization. The majority of animals used are genetically engineered mice. In the past 5 years, the daily average cage counts increased 52%, from 13,243 cages in 2002-03 to 20,132 cages of animals in 2006-07. Future plans include renovation and expansion of the South Campus animal facility, and upgrading and implementing computer applications for business operations and preclinical drug development. Additionally, RASF-Houston and Smithville have jointly submitted a startup proposal to develop a Mutant Mouse Pathology Service to serve all MDACC investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-37S2
Application #
8530370
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
37
Fiscal Year
2012
Total Cost
$2,882
Indirect Cost
$1,058
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Korch, Christopher; Hall, Erin M; Dirks, Wilhelm G et al. (2018) Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line. Int J Cancer 142:561-572
Lee, Jong-Ho; Liu, Rui; Li, Jing et al. (2018) EGFR-Phosphorylated Platelet Isoform of Phosphofructokinase 1 Promotes PI3K Activation. Mol Cell 70:197-210.e7
Brown, Justin C; Troxel, Andrea B; Ky, Bonnie et al. (2018) Dose-response Effects of Aerobic Exercise Among Colon Cancer Survivors: A Randomized Phase II Trial. Clin Colorectal Cancer 17:32-40
Zhang, Hong; Wang, Yirong; Li, Jun et al. (2018) Biosynthetic energy cost for amino acids decreases in cancer evolution. Nat Commun 9:4124
Vilar-Compte, Diana; Shah, Dimpy P; Vanichanan, Jakapat et al. (2018) Influenza in patients with hematological malignancies: Experience at two comprehensive cancer centers. J Med Virol 90:50-60
Bambhroliya, Arvind; Van Wyhe, Renae D; Kumar, Swaminathan et al. (2018) Gene set analysis of post-lactational mammary gland involution gene signatures in inflammatory and triple-negative breast cancer. PLoS One 13:e0192689
Koay, Eugene J; Lee, Yeonju; Cristini, Vittorio et al. (2018) A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 24:5883-5894
Jain, N; Zhu, H; Khashab, T et al. (2018) Targeting nucleolin for better survival in diffuse large B-cell lymphoma. Leukemia 32:663-674
Parker, Patricia A; Peterson, Susan K; Shen, Yu et al. (2018) Prospective Study of Psychosocial Outcomes of Having Contralateral Prophylactic Mastectomy Among Women With Nonhereditary Breast Cancer. J Clin Oncol 36:2630-2638
Fathi, Amir T; Erba, Harry P; Lancet, Jeffrey E et al. (2018) A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. Blood 132:1125-1133

Showing the most recent 10 out of 12418 publications